Crinetics Pharmaceuticals (CRNX) Accounts Payables (2017 - 2026)

Crinetics Pharmaceuticals' Accounts Payables history runs 10 years deep, the most recent figure standing at $37.5 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 280.89% year-over-year to $37.5 million; the TTM figure through Mar 2026 stood at $37.5 million (up 280.89% YoY), while the FY2025 annual figure was $41.8 million, up 94.56% from the prior year.
• Accounts Payables was $37.5 million for Q1 2026 at Crinetics Pharmaceuticals, down from $41.8 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $41.8 million in Q4 2025 to a low of $5.9 million in Q1 2023.
• Historically, Accounts Payables has averaged $19.5 million across 5 years, with a median of $18.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables surged 386.56% in 2024, then slumped 65.69% in 2025.
• A 5-year view of Accounts Payables shows it stood at $6.9 million in 2022, then retreated by 4.87% to $6.5 million in 2023, then soared by 227.87% to $21.5 million in 2024, then surged by 94.56% to $41.8 million in 2025, then slipped by 10.25% to $37.5 million in 2026.
• The last three Accounts Payables figures came in at $37.5 million (Q1 2026), $41.8 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.